
Opinion|Videos|September 26, 2024
Key Highlights From NATALEE at ESMO 2024
Panelists discuss how the NATALEE study at ESMO 2024 presented updates on primary, secondary, and exploratory end points for evaluating a new cancer treatment.
Advertisement
Episodes in this series
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5








































